摘要
目的研究骨巨细胞瘤(GCT)骨皮质破坏与肿瘤组织中P65、RANKL、OPG、MMP-9表达程度的关系,初步探讨MRI所示的侵袭性征象所代表的生物学行为。方法搜集2010年8月至2012年1月本院诊治的28例GCT患者,根据MRI表现有无骨皮质明显中断和软组织肿块形成分为2组,运用半定量逆转录聚合酶链式反应(RT-PCR)的方法检测各个肿瘤组织中P65、RANKL、OPG、MMP-9的mRNA的表达程度,分析2组间P65、RANKL、OPG、MMP-9的mRNA的表达程度有无差异以及各种蛋白的mRNA表达间有无相关性。所得的数据采用SPSS 13.0统计软件,采用秩和检验法和相关分析法,以P≤0.05为差异有统计学意义。结果有骨皮质明显中断和软组织肿块形成的GCT较无骨皮质明显中断和软组织肿块形成的GCT的P65、RANKL、MMP-9的表达量升高,OPG的表达无统计学差异。结论MRI表现有骨皮质中断征象的GCT,其骨质破坏蛋白表达增加,提示GCT中骨质破坏活动增加。
Objective To discuss the correlation between cortical destruction observed on MRI and the expressions of P65, receptor activator of NF-kB ligand ( RANKL), osteoprotegerin (OPG) and matrix metalloproteinase-9 (MMP-9) in giant cell tumor of bone (GCT), and to preliminary investigate the biological behavior which was presented by invasive signs observed on MRI. Methods A total of 28 patients with GCT, who were treated at authors' hospital during the period from August 2010 to January 2012, were collected. Based on the presence or absence of cortical disruption and the softtissue mass, the patients were divided into the study group and the control group respectively. The expression levels of P65, RANKL, OPG and MMP-9 mRNA were determined by using semiquantitative RT-PCR technique. The data was sub- jected to rank sum test or correlation analysis using SPSS13.0 software with P~〈0.05 being considered as statistically signif- icant. Results The expression levels of P65, RANKL and MMP-9 mRNA in the study group were significantly higher than those in the control group, while the difference in the expression level of OPG mRNA between the two groups was not statistically significant. Conclusion In giant cell tumor of bone, when cortical disruption and the soft-tissue mass are present on MRI, the expression level of bone destruction is increased, suggesting that the bony destruction activity is en- hanced within the giant cell turaor.
出处
《临床放射学杂志》
CSCD
北大核心
2015年第5期768-772,共5页
Journal of Clinical Radiology
关键词
骨巨细胞瘤
NF-KB
RANKL
OPG
MMP-9
Giant cell tumor of bone Receptor activator of nuclear factor-kB ligand osteoprotegerin Matrix metallo-proteinase-9